sector medic suppli devic
messag report disappoint sale miss manag
lower guidanc take account fewer patient add compani
made solid progress reimburs front cover live
concern recent execut departur rep layoff could imped abil
build momentum even market access improv lower pt
given scale cgm opportun low expect
reflect stock current level continu see risk/reward posit
howev believ upsid like limit begin demonstr
good despit disappoint mani front made
major stride establish reimburs eversens one
manag key object come year conjunct releas
compani announc final payment eversens defin
medic benefit part medicar patient bring total number cover
live across countri medicar polici go effect jan
importantli sever biggest commerci payer win also come
last day mean start impact combin
decis posit compani recogn higher percentag gross
revenu move begin drive broader adopt market access
becom less stumbl block patient interest eversens
bad encourag progress reimburs view
lack increment commerci momentum quarter disappoint gross domest
revenu fell meanwhil portion sale
defer increas result recogn revenu
domest vs last quarter recent reimburs win help
reduc gross-to-net adjust go forward account convent asid howev
senseon simpli driven level adopt expect year given
consist posit patient feedback gotten eversens appeal
implant cgm system manag expect exit instal
base patient compar origin target beyond challeng
reimburs compani also cite low product awar lack access
implant physician impedi manag hope address former
continu invest digit market campaign meanwhil
initi new program call certifi eversens specialist ce network group
train sensor insert remov specialist endocrinologist wish
perform procedur refer patient implant manag
hope hub-and-spok model remov anoth barrier adopt
ugli tuesday call ceo tim goodnow announc jon isaacson cfo
mike gill vice-president gener manag leav compani pursu
interest mr gill diabet alum join senseon april mr isaacson
post sinc januari departur might expect
year turnov come critic time compani
involv perhap two import role within execut team moment
given need deliv sale ramp set appropri expect
manag balanc sheet along line announc restructur
plan design reduc expens entail headcount reduct across
compani cut number sale rep agre conserv
cash prioriti concern extent cut combin
major leadership chang across organ could imped abil build
momentum star begin align front
page analyst certif import disclosur
question answer low expect skew risk/reward posit
manag expect revenu come vs prior
guidanc yoy biggest driver reduc outlook
lower expect contribut sale model call senseon
post net loss per share total revenu cc
compar prior forecast net loss per share
sale lower revenu forecast yet despit
conserv assumpt around patient add continu see ampl opportun
drive signific growth next year given size cgm
market patient global alon eversens uniqu form factor
share trade ntm sale believ stock embed low
expect compani achiev ramp new price target
previous base multipl revis forward ntm
page analyst certif import disclosur
senseon develop novel continu glucos monitor technolog aid
treatment manag diabet compani eversens system
becam first commerci avail long-term implant cgm sensor launch
follow european approv eversens xl extend sensor
lifespan day day follow june fda approv
commerci eversens began last year despit compel clinic evid
support use cgm penetr remain rel low today
type popul insulin-intens type patient recent advanc
address mani histor shortcom technolog howev lead
dramat increas cgm penetr posit technolog becom
standard care insulin-intens diabet next year
believ eversens offer varieti advantag tradit transcutan cgm
system featur sensor must swap everi day approach
sever drawback includ risk infect skin irrit weekli sensor
insert conspicu natur sensor/transmitt patient bodi
case need carri separ receiv alert glucos excurs
eversens address mani issu sensor implant subcutan
quick office-bas procedur provid accur glucos read month
need replac feedback physician patient suggest
us potenti take meaning share cgm market
eversens roll later year model assum captur
 new patient start next four year exit share
domest cgm instal base even modest penetr enough drive
overal revenu growth
valu primarili ev/sal basi use repres group
small-to-mid cap med-tech name similar growth characterist comp base
guggenheim factset consensu estim group current trade ntm
sale compar multipl ntm revenu forecast
lower price target base previous
multipl revis forward ntm sale estim signific upsid potenti
target current level assign buy rate
downsid risk rate price target includ disappoint commerci adopt
eversens system and/or europ failur keep pace
rapidli evolv cgm market potenti need compani rais
addit capit prior reach profit
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
revenu million usd
revenu compon
compani report guggenheim secur llc estim
page analyst certif import disclosur
